[Skip to Navigation]
Sign In
June 13, 2022

Errors in Results in Abstract and Text and in Table 1

JAMA Neurol. 2022;79(7):727. doi:10.1001/jamaneurol.2022.1581

In the article titled “Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis,”1 published in the February 2022 issue, there was a transcription error in the IQR of the median time of treatment with edaravone in the Results section of the Abstract and text and transcription errors in the data in the follow-up section of Table 1. This article was corrected online.

Witzel S, Maier A, Steinbach R, et al; German Motor Neuron Disease Network (MND-NET). Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis.  JAMA Neurol. 2022;79(2):121-130. doi:10.1001/jamaneurol.2021.4893PubMedCrossref